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Abstract
Rio1 kinase is an essential ribosome-processing factor required for proper maturation of 40 S ribosomal subunit. Although
its structure is known, several questions regarding its functional remain to be addressed. We report that both Archaeoglobus
fulgidus and human Rio1 bind more tightly to an adenosine analog, toyocamycin, than to ATP. Toyocamycin has antibiotic,
antiviral and cytotoxic properties, and is known to inhibit ribosome biogenesis, specifically the maturation of 40 S. We
determined the X-ray crystal structure of toyocamycin bound to Rio1 at 2.0 A ˚ and demonstrated that toyocamycin binds in
the ATP binding pocket of the protein. Despite this, measured steady state kinetics were inconsistent with strict competitive
inhibition by toyocamycin. In analyzing this interaction, we discovered that Rio1 is capable of accessing multiple distinct
oligomeric states and that toyocamycin may inhibit Rio1 by stabilizing a less catalytically active oligomer. We also present
evidence of substrate inhibition by high concentrations of ATP for both archaeal and human Rio1. Oligomeric state studies
show both proteins access a higher order oligomeric state in the presence of ATP. The study revealed that
autophosphorylation by Rio1 reduces oligomer formation and promotes monomerization, resulting in the most active
species. Taken together, these results suggest the activity of Rio1 may be modulated by regulating its oligomerization
properties in a conserved mechanism, identifies the first ribosome processing target of toyocamycin and presents the first
small molecule inhibitor of Rio1 kinase activity.
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Introduction
Protein kinases are involved in a large variety of cellular
processes including regulation of gene expression, DNA transcrip-
tion, signal transduction, cell cycle progression and ribosome
biogenesis [1–3]. In eukaryotes, protein kinases are among the
largest superfamilies with over 500 members identified in the
human genome [4]. Of these, 40 are classified as atypical protein
kinases (aPKs), while the rest are considered classical eukaryotic
protein kinases (ePKs) [4]. Both classes of protein kinases catalyze
the phosphorylation of serine, threonine or tyrosine residues.
One family of aPKs is the RIO kinase family that comprises
Rio1, Rio2, Rio3 and a group found only in some eubacteria,
RioB [5]. Rio1 and Rio2 are highly conserved and present in all
archaeal and eukaryotic organisms, whereas Rio3 is only found in
metazoa [5]. Previously solved crystal structures of Archaeoglobus
fulgidus Rio1 (afRio1) and Rio2 (afRio2) have shown the RIO
domain is a trimmed version of the ePK catalytic domain with an
additional conserved N-terminal a-helix [5,6]. The ePK catalytic
domain is comprised of 250 to 300 amino acids consisting of
twelve subdomains that are composed of conserved structural
elements [7]. The twelve subdomains include a nucleotide-binding
loop, a hinge region between the N- and C-terminal domains that
participates in binding the adenine moiety of ATP, a catalytic loop
consisting of catalytic Asp and Asn residues, a metal binding loop
(DFG loop), substrate binding subdomains and the activation loop
(APE loop) that is usually involved in regulation of kinase activity
[7]. The RIO domain lacks the activation loop, most of the surface
required for peptide substrate binding and recognition in ePK and
binds nucleotides in a different conformation compared to the
ePKs, suggesting a difference in the substrate interactions and
catalytic mechanism [5,6]. All RIO kinases purified to date are
capable of autophosphorylation on serine at sites of varying
sequence [5,8,9], and recently, it was reported that Rio1 from the
archaeon Haloferax volcanii is capable of phosphorylating a1, a 20 S
proteosome core particle subunit [10]. Rio1 autophosphorylates in
trans, such that one molecule of Rio1 will autophosphorylate
another [9].
Rio1 kinase is the founding member of the RIO family [8]. Rio1
is involved in ribosome biogenesis, cell cycle progression and
chromosome maintenance [8,11,12]. Studies have shown that
Saccharomyces cerevisiae (yeast) Rio1 is an essential gene and a non-
ribosomal factor required for the processing of 20 S pre-rRNA to
mature 18 S rRNA, the RNA component of the 40 S subunit.
Depletion of Rio1 in cells leads to accumulation of 20 S pre-rRNA
and cell cycle arrest [13]. Ribosome biogenesis is a highly
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number of processing factors. In eukaryotic cells, it is estimated
that over 200 non-ribosomal protein factors are required,
including endo- and exonucleases, chaperones, RNA helicases,
RNA modifying enzymes and small nucleolar ribonucleoprotein
particles (snoRNPs) [3,14,15]. Ribosome biogenesis is also tightly
linked to cell cycle progression and proliferation [16,17]. In fact, a
distinguishing characteristic of cancer cells is enlarged nucleoli -
the compartment where rRNA synthesis and processing occurs
[18]. Therefore, modulating the rate of ribosome biogenesis is
likely to regulate cell proliferation. One possible avenue for
modulating ribosome biogenesis is through targeting and inhib-
iting proteins required for rRNA processing such as Rio1 kinase.
In initial attempts to find starting fragments targeting the afRio1
ATP-binding site, we employed a structure-based approach to
identify adenosine analogs that we would predict to bind tightly to
Rio1. We identified toyocamycin (Fig. 1A), a 7-cyano-7-deazaa-
denosine produced by Streptomyces toyocaensis (a gram-positive
bacterium) as a tight binding adenosine analog. Previous studies
that date back to 1968 showed that low concentrations of
toyocamycin selectively inhibited 28 S and 18 S rRNA maturation
in mammalian cells [19]. Further investigations on the effect of
toyocamycin on several cancer cell lines such as HeLa cells, colon
carcinoma cells and chick embryo cells infected with MC29 Avian
Leukosis virus also revealed the inhibition of rRNA processing
[20–22]. Toyocamycin is also capable of inhibiting kinases such as
phosphatidylinositol kinase, rhodopsin kinase and adenosine
kinase from Mycobacterium tuberculosis [23–25].
We hereby present a crystal structure of toyocamycin bound to
afRio1 at 2.0 A ˚ resolution and employ structural analysis to
characterize the interactions. This complex structure shows
binding of toyocamycin to the ATP binding pocket and further
characterization on the effect of toyocamycin on afRio1 enzymatic
activity reveals inhibition by association of oligomers. Interaction
of afRio1 with toyocamycin and presence of multiple oligomeric
states appears to be conserved in human Rio1 kinase (hRio1). We
therefore identify a tight binding analog and present the first
report of a compound that inhibits the phosphorylation activity of
Rio1 kinase. We also directly link toyocamycin to rRNA
processing inhibition via inhibition of Rio1, a ribosome-processing
factor, and our results suggest a role for Rio1 autophosphorylation
in modulation of the kinase’s oligomeric properties.
Materials and Methods
Protein Expression and Purification of afRio1 Kinase and
Y200D mutant
The full-length afRio1 was expressed and purified as previously
described [9]. Site- directed mutagenesis was performed using the
QuikChange
TM Lightning kit (Agilent Technologies) according to
the manufacturer’s instructions. Mutagenic primers used were
59GGTGCATGCGGATCTGAGCGAAGATAACATTATG-
TATATTGATAAA 39as the sense primer and 59 TTTTAT-
CAATATACATAATGTTATCTTCGCTCAGATCCGCATG-
CACC 39 as the antisense primer. Protein expression and
purification of afRio1Y200D followed the same protocol as the
full-length afRio1 [9] with one modification. After lysis, the cells
were heated at 68uC instead of 75uC for 15 minutes to denature
E. coli proteins. AfRio1 purified under these conditions is not
autophosphorylated, as confirmed by mass spectrometry (data not
shown) and structural data previously reported [26].
Figure 1. Adenosine analogs screened for Rio1 binding
activity. A. Chemical structures of molecules used in this study.
Thermal shift data for B. afRio1 and C. hRio1. Difference between
melting temperatures (Tm) for unbound afRio1 and complexes with
each compound plotted. Actual thermal shift plots provided in Fig. S1.
doi:10.1371/journal.pone.0037371.g001
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A construct of hRio1 containing residues 106 to 494 was
expressed and purified as previously reported for afRio1 [9] with a
few modifications. After lysis, the cells were immediately
centrifuged at 18,000 rpm for 30 minutes at 4uC with no
denaturation step. The buffer used during the size exclusion
purification step, contained 50 mM Tris pH 8.0, 200 mM NaCl,
and 0.2% b-mercaptoethanol. To prevent autophosphorylation,
the protein is purified in the presence of 1 mM adenosine, which
prevents autophosphorylation.
Thermofluor Assays
All afRio1 assays were carried out in 50 mM Tris pH 8.0,
75 mM NaCl and 2 mM MgCl2. Reactions of 50 ml of buffer
containing afRio1 and adenosine analogs at a concentration of
1.0 mg/ml protein and 2 mM ligand respectively were incubated
at 25uC for 30 minutes. 50 ml of Sypro-Orange
TM dye (Sigma-
Aldrich) diluted to 2X in reaction buffer (above) was then added to
the reactions. As a reference, reactions were also set up in which
no ligand was added. The reactions were heated from 30uCt o
98uC using a Bio-Rad Mini-Opticon
TM thermal cycler at a rate of
0.2uC per second with an initial holding time of 2 minutes. HRio1
assays followed the same protocol as afRio1 and were carried out
in a buffer containing 50 mM Tris pH 8.0, 200 mM NaCl and
0.2% b-mercaptoethanol. HRio1 reactions were initially incubat-
ed at 4uC for 30 minutes and then heated from 4uCt o9 8 uC using
the thermal cycler. The change in fluorescence intensity (I) was
monitored as the temperature increased. All measurements were
done in triplicates and the melting temperature (Tm) was
determined as the inflection point of the melting curve (or the
peak of dI/dT). Shifts in melting temperature (Tm) were calculated
as the difference between the Tm of the control reaction (unbound
afRio1/hRio1) and Tm of the reaction containing the compound
of interest.
Co-crystallization of afRio1 with Toyocamycin
Purified afRio1 was concentrated to 21 mg/ml in a buffer
containing 10 mM Tris pH 8.0, 10 mM NaCl, and 0.2% b-
mercaptoethanol. AfRio1 was incubated with 2 mM toyocamycin
at 25uC for one hour and the complex was subjected to robotic
sparse matrix screening in 96 well plates using the sitting drop
method in three different afRio1-toyocamycin complex to well
solution ratios (1:2, 1:1, 2:1) using the Phoenix
TM Liquid Handing
system (Art Robbins). We used six commercially available
screening matrices; Index
TM (Hampton Research), Cryos Suite
TM
(Qiagen), PEGs Suite
TM (Qiagen), Wizard
TM I, II and III
(Emerald Biosystems). The plates were incubated at 20uC and
crystals were observed after seven days in the PEGs Suite
TM
screen. These crystals grew in the 1:2 protein to well solution ratio
in 0.2 M Mg (CH3COO)2, 24% PEG 3350, pH 8.0. The crystals
were optimized using the hanging drop method with a precipitant
range of 14%–32% PEG 3350 and the salt range was varied from
0.15 M to 0.3 M. The optimized trays were incubated at 20uC
and we were able to obtain good quality crystals (12065065 mm)
after one week.
Crystal Structure Determination and Refinement
AfRio1-toyocamycin crystals were flash frozen in well solution
containing 20% (v/v) glycerol. Data was collected at 100 K at the
NE-CAT beamline at the Advanced Photon Source (APS),
Argonne, IL, USA. All data was indexed, integrated and scaled
using HKL2000 program [27]. Data statistics are provided in
Table 1. A previously solved structure of afRio1 bound to ATP
and Mn
2+ (PDB ID: 1ZP9) was used as a molecular replacement
model to phase the afRio1-toyocamycin complex structure. The
afRio1-toyocamycin data set was phased using MOLREP [28–30]
as part of CCP4i and subjected to several rounds of building using
the model-building program COOT [31] and several rounds of
refinement using REFMAC5 [32] and PHENIX [33,34]. Data
collection and refinement statistics are provided in Table 1. The
coordinates and structure factors have been deposited in the
Protein Data Bank (PDB ID: 3RE4).
Steady State Enzymatic Assays
In order to determine the Km of afRio1 for ATP, 0.5 mgo f
purified afRio1 and 10 mg of MBP was added to a 30 ml reaction
volume containing 50 mM Tris pH 8.0, 50 mM NaCl, 2 mM
MgCl2 and 0.2% b-mercaptoethanol. The final concentration of
ATP added was varied from 1610
26 M to 7.9610
29 M. For each
reaction, 5 mCi of c-
32P labeled ATP was added and the specific
activity determined for each concentration. Each reaction was
incubated at 37uC and stopped at specific time points (0, 1, 2, 4, 6,
8, 10, 15, 20, 30 and 40 mins) by adding 8 ml of SDS-PAGE
loading dye and heating the reaction at 95uC for 5 minutes. All
reactions were carried out in triplicates. The reaction mixtures
were run on NuPAGE
TM 4–12% Bis-Tris denaturing gels
(Invitrogen) at 200 V for 30 mins in order to separate afRio1,
ATP and MBP. The gels were dried and exposed on a
phosphorimager screen for 15 hours. Total intensity was
quantified using ImageQuant to determine moles of c-
32P
Table 1. Data Collection and Refinement Statistics.
Data collection: afRio1/Toyocamycin
Space group P21
Cell dimensions
a, b, c (A ˚) 52.8, 72.6, 60.6
b (u) 90.2
Molecules/Asym. unit 2
Wavelength (A ˚) 0.97919
Resolution (A ˚) 40-2.00
Rsym (last shell) 0.069 (0.282)
I/sI 18.2 (5.5)
Completeness (%) 97.7 (96.1)
Redundancy 4.0 (3.9)
Refinement:
Resolution (A ˚) 34.9-2.00
Residues 503
Rwork/Rfree (%) 21.5/26.0
Waters 175
Mean B-factors (A ˚)
2 Residues, Water,
Ligands
30.6, 34.6, 27.6
RMS deviations:
Bond lengths (A ˚) 0.011
Bond angles (u) 1.385
Ramachandran plot:
Favored 95.1%
Additional Allowed 4.9%
Disallowed 0.0%
doi:10.1371/journal.pone.0037371.t001
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protocol was followed with the addition of toyocamycin to the
reaction assay. Inhibition studies were carried out at three different
concentrations of toyocamycin 20 nM, 40 nM and 60 nM. For
autophosphorylated afRio1 samples, the protein was first incubat-
ed at 37uC in 50 mM Tris pH 8.0, 50 mM NaCl, 2 mM MgCl2
and 0.2% b-mercaptoethanol with 1 mM ATP for 1 hr and further
purified by size exclusion chromatography using the reaction
buffer in the absence of ATP. The enzymatic assays followed the
same protocol as the unphosphorylated afRio1.
Substrate Inhibition by High Concentrations of ATP
Data shown in Fig. 2B and C were produced by assays that
followed the same protocol as steady state enzymatic assays with a
few modifications. 1 mg of afRio1 and 5 mg of MBP were used in
the reaction and ATP concentrations were varied from 1610
24 M
to 1.0610
27 M. All reactions were incubated at 37uC for
45 minutes. For the hRio1 assay, 5 mg of hRio1 was added to a
buffer containing 20 mM Tris pH 8.0, 100 mM NaCl, and 2 mM
MgCl2 and different amounts of ATP concentrations that varied
from 1.8610
23 M to 9.0610
27 M. The hRio1 reactions were
incubated at 25uC for 1 hour.
Sedimentation Equilibrium Experiments
All afRio1 samples were dialyzed against 50 mM Tris pH 8.0,
50 mM NaCl, 2 mM MgCl2 and 0.2% b-mercaptoethanol. The
samples were prepared in three different concentrations of 0.5,
0.25 and 0.125 mg/ml each. In order to ensure that there was no
absorbance interference from toyocamycin, ATP and ADP, an
absorbance spectrum at different concentrations for each com-
pound was collected at 280 nm. The highest concentration that
showed no absorbance at 280 nm was 1610
25 M for all three
compounds, which is at saturation levels for afRio1 binding. This
concentration was used in the experiments. For autophosphory-
lated afRio1 samples, the protein was first incubated at 37uCi n
sedimentation buffer with 1 mM ATP for 1 hr and further purified
by size exclusion chromatography in the sedimentation equilibri-
um buffer. Analysis of autophosphorylated afRio1 in the presence
of ATP or toyocamycin, the appropriate compound was added to
the sample for a final concentration of 1610
25 M. As with
unphosphorylated afRio1 the protein samples were analyzed at
three different concentrations of 0.5, 0.25 and 0.125 mg/ml each.
The experiments were carried out at 20uC in a Beckman XL-I
Analytical Ultracentrifuge and data collected at 280 nm using six
channel Epon centerpieces with a 12 mm path-length containing
110 ml samples and 120 ml buffer references and run at three
speeds 18000 rpm, 22000 rpm and 26000 rpm. Data was
analyzed using the software, WinNonlin [35].
Size Exclusion Chromatography of afRio1 and hRio1
In order to determine the oligomeric states of ligand free,
adenosine-bound, ATP-bound and autophosphorylated Rio1, the
samples with a final protein concentration of 3 mg/ml were
analyzed using size exclusion chromatography. Autophosphory-
lated afRio1 was prepared as described in the sedimentation
equilibrium section (above). For autophosphorylated hRio1
sample, the protein was incubated at 25uC for 1 hr in 50 mM
Tris pH 8.0, 200 mM NaCl, 2 mM MgCl2 and 0.2% b-
mercaptoethanol. An analytical Superdex
TM 200 column (GE
Healthcare) was equilibrated with a buffer containing 50 mM Tris
pH 8.0, 200 mM NaCl and 0.2% b-mercaptoethanol. The
calibration proteins, ribonuclease, ovalbumin, conalbumin and
aldolase (GE Healthcare), were diluted with 50 mM Tris pH 8.0
and 200 mM NaCl for a final concentration of 3 mg/ml. All four
calibration proteins were mixed together, centrifuged to remove
any precipitants and loaded onto the column. Finally, the Rio1
protein samples were diluted in equilibration buffer containing
Figure 2. Steady state analyses of afRio1. A. Vo vs [ATP] curves for
afRio1 in the presence and absence of 20, 40 and 60 nM toyocamycin.
B. Autoradiogram showing the transfer of
32P-labelled phosphate to
afRio1 (by autophosphorylation) and MBP as a function of increasing
ATP concentration [ATP]. C. Vo vs [ATP] curves for afRio1 showing
substrate inhibition at high concentrations of ATP. D. Autoradiogram
showing autophosphorylation of human Rio1 as a function of
increasing [ATP]. E.Vo vs [ATP] curves for phosphorylated afRio1 in the
presence and absence of 40 and 60 toyocamycin.
doi:10.1371/journal.pone.0037371.g002
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were monitored by absorbance at 280 nm.
Results
Identification of Small Molecule Stabilizers of afRio1
Kinase
In an effort to identify molecules that would act as tight binding
fragments for the design of specific RIO kinase inhibitors, we
tested N7-substituted analogs of adenosine for binding to afRio1.
Based on the observation of an open pocket near the N7 of the
adenine ring in the crystal structure of the Rio1-ATP binding site,
we determined that these analogs would be a good starting point.
Using thermal shift assays that monitor the shift in melting
temperature (Tm) of bound afRio1 in comparison to unbound
afRio1, we identified two adenosine analogs, sangivamycin and
toyocamycin, that resulted in a significant increase in the Tm of
afRio1 compared to the unbound protein (Fig. 1B, Fig. S1A). The
Tm of unbound afRio1 is 76uC 60.4uC and in the presence of
ATP and magnesium (Mg
2+) the Tm shifts to 82uC 61.0uC, a 6uC
increase. The Tm in the presence of sangivamycin and
toyocamycin was 82uC 61.2uC and 88uC 60.1uC respectively,
which is similar to ATP/Mg
2+ in the case of sangivamycin, and a
12uC shift for toyocamycin (Fig. 1B). We also tested 7-
methylinosine, which we did not expect to bind optimally because
of the carbonyl moiety at the N6 position. We observed a 3uC
shift, indicating weaker binding than ATP/Mg
2+. Previous afRio1
crystal structures that have been solved in the presence of
adenosine, ADP and ATP show that N6 position of the adenine
moiety requires a hydrogen donor to interact with the peptidyl
carbonyl oxygen of Glu 148 [26]. The data was a clear indication
that toyocamycin binds to afRio1 more tightly than ATP/Mg
2+,
despite the lack of a triphosphate moiety and hence absence of
metal ion interactions. The same compounds used in afRio1 assay
(Fig. 1A) were tested for binding to hRio1 kinase. Unbound hRio1
kinase had a Tm of 41.161.1uC. The Tm increased to 53.261.8uC
in the presence of toyocamycin, a 12.1uC increase, similar to what
is observed with afRio1. In the presence of either sangivamycin or
7-methylinosine, the Tm was 50.7uC, showing an increase of
9.6uC. When ATP/Mg
2+ is added to hRio1, the Tm is
50.061.2uC corresponding in an 8.9uC shift. Taken together this
data shows conserved high affinity for toyocamycin in both the
archaeal and human Rio1.
Structure Determination of the AfRio1/Toyocamycin
Complex
In order to study how toyocamycin is able to stabilize afRio1 to
a greater extent than ATP/Mg
2+, we determined the crystal
structure of afRio1 bound to toyocamycin. The completely refined
structure contained two molecules of the afRio1/toyocamycin
complex per asymmetric unit with residues 3-258 for each
molecule (Fig. 3). The afRio1 structure consists of an N-terminal
domain (N-lobe) that consists of a a-helical region and a twisted b-
sheet that contains the phosphate interacting loop (P-loop) and an
a-helical C-terminal region (C-lobe) that houses the catalytic and
metal binding residues. The N- and C-lobes are connected by a
hinge region, and between the two domains is a cleft that buries
the 7-cyano-7-deazaadenine ring of toyocamycin. Rio1 has a
flexible loop consisting of Arg 83-Glu 111 that changes
conformation when ATP/Mn
2+ is bound. In the afRio1/
toyocamycin complex, part of that flexible loop, residues 86–90
in chain A and residues 86–93 in chain B, are not observed in the
electron density map. This is similar to the structure of ATP/Mn
2+
bound to afRio1 for which no electron density was observed for
residues 85–91. The RMSD between the two molecules in the
asymmetric unit is 0.024 A ˚ 2 for 240 residues (Fig. S2).
Interactions Between Toyocamycin and Rio1
A difference electron density (Fo-Fc) map, generated by refining
the search model in the absence of any ligand revealed an electron
density for toyocamycin (Fig. 4A). Each toyocamycin molecule in
the asymmetric unit had a low average B-factor of 27.5 and 27.6
Figure 3. Dimer of afRio1/toyocamycin (toyo) complex observed in the asymmetric unit.
doi:10.1371/journal.pone.0037371.g003
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and ATP binding sites demonstrates that toyocamycin binds to the
same site as ATP (Fig S3). Toyocamycin is buried in the active site
pocket that features hydrophobic contact with Val 63, Ile 55 and
Ala 78 from the N-lobe, Pro 156, Met 147,Phe 149 and Ile 150
from the hinge, and Met 203 and Ile 211 from the C-lobe. In
addition, toyocamycin participates in ten hydrogen bond interac-
tions. There is one direct interaction from the peptidyl carbonyl
oxygen of Glu 148 to the amino group N6 and another from the
indole nitrogen, N1 to the peptidyl amine group of Ile 150
(Fig. 4B). This is similar to the binding mode observed in this
region with ATP [5]. Another hydrogen bond is seen between the
7-cyano group to a water molecule contacting the carbonyl side
chain of Glu 120 and peptidyl amine group of Asp 212 (Fig. 4B).
This water molecule is seen in all available structures of afRio1
and in the ATP/Mn
2+ bound afRio1 it mediates a hydrogen bond
between Glu 120 and c-phosphate. The ribose 39 hydroxyl
participates in water-mediated contacts with the side chain of Glu
162, with the peptidyl carbonyl oxygen of Tyr 200 and with the
peptidyl carbonyl oxygen of Ile 55. The ribose 29 hydroxyl
participates in water-mediated hydrogen bonds with the peptidyl
carbonyl oxygens of Ile 55, Ala 157 and Glu 162. These water-
mediated interactions are not observed in the ATP/Mn
2+ bound
to afRio1 structure. The 59 hydroxyl is in hydrogen bonding
distance of Asp 212 and involved in a water-mediated hydrogen
bond interaction with the peptidyl carbonyl oxygen of Tyr 200
(Fig. 4B). In the ATP/Mn
2+ bound to afRio1 complex, Asp 212
side chain directly hydrogen bonds with the c-phosphate, and is
liganded to the Mn
2+ that coordinates the a- and b-phosphates.
Steady state kinetic analyses of afRio1
In order to determine whether toyocamycin acts as a strict
competitive inhibitor of afRio1 kinase activity, we determined the
steady state kinetic parameters for afRio1 in the presence and
absence of toyocamycin. We determined the Km for ATP and
Vmax of afRio1 in an assay that measured the incorporation of
c-
32P from ATP into myelin basic protein (MBP), a commonly
used general kinase substrate that is measurably phosphorylated by
afRio1 [26]. The Km,ATP was 0.4 mM( 60.1) whereas the Vmax
was 2.6 pmol/sec (Table 2, Fig. 2A), determined by non-linear
least squares fits of the Michaelis-Menten equation Vo=(V-
max[S])/(Km + [S]) to plots of the initial velocity (Vo) as a function
of ATP concentration ([ATP] or [S]). Standard error estimations
are reported from the fit to the mean of triplicate measurements.
We also observed that Rio1 kinase catalytic activity begins to
decrease at high [ATP] (Fig. 2B). At [ATP] above 0.1 mM, kinase
activity begins to drop until at 100 mM it becomes almost
unmeasurable. Figure 2C shows a curve fit using a substrate
inhibition model with the equation Vo=( V max[S])/(Km +
[S]([1+[S]/Ki,ATP)) was used to fit the Vo vs [S] plots, where [S]
is [ATP], and Ki,ATP is the substrate inhibition constant. The
Km,ATP determined using this model was 0.8 mM( 60.2), and
Ki,ATP was 7.1 mM. This substrate inhibition behavior is also
observed in similar assay using the human Rio1 kinase (Fig. 2D).
Therefore, our analyses of steady state parameters were limited to
data collected at low [ATP].
The steady state kinetic parameters were also determined in the
presence of three different concentrations of toyocamycin based on
the equilibrium dissociation constant (Kd) for toyocamycin binding
which was estimated to be 40 nM (data not shown). An initial non-
linear least squares fit using the Michaelis-Menten equation
Figure 4. Interactions between afRio1 and toyocamycin. A. Active site of afRio1 overlaid with difference density (Fo-Fc) map calculated using
model in which toyocamycin (toyo) is omitted (contoured at 2.5s). Some of the residues lining the hydrophobic pocket of the active site are labeled.
B. Hydrogen bonding interactions (dashed lines) observed between toyocamycin and afRio1.
doi:10.1371/journal.pone.0037371.g004
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the apparent Km was determined to be 0.2 mM( 60.03) with a
Vmax of 0.6 pmol/sec. This shows a 1.8 fold decrease in the Km
and a 4.5 fold decrease in the Vmax. A change in both Km and
Vmax is inconsistent with strict competitive inhibition, in which
case one would expect an increase in the Km and no change in the
Vmax. At 20 nM, the apparent Km is within error of the Km
determined without inhibitor and at 60 nM it is lower than at
40 nM (Table 2). The Vmax shows a steady decrease as inhibitor
concentration is increased (Table 2 and Fig. 2A). Since
toyocamycin decreases Vmax, we tested different inhibition
models for a global fit of Vo vs [S] plots for the data sets
(excluding [S] above 1 mM). The best global fit was to a mixed
inhibition model with the modified Michaelis-Menten equation,
Vo=(Vmax [S])/(aKm + a’[S]), where a=1+([I]/Ki),
a’=1+([I]/Ki’) and Ki and Ki’ are the inhibition constants. The
inhibition constants in the presence of a) 20 nM toyocamycin were
10.7 nM and 40 nM, b) in the presence of 40 nM toyocamycin
were 26.7 nM and 11.4 nM, and c) in the presence of 60 nM
toyocamycin were 3.8 nM and 5.5 nM as reported on Table 2
(curve-fits shown in Fig. 2A). Steady state kinetics data in the
presence of toyocamycin had the best global fit to a mixed
inhibition model that encompasses both competitive and uncom-
petitive inhibition. Crystallographic studies support competitive
inhibition as we observe binding of toyocamycin to the ATP
pocket, and not to any other site in the presence of a saturating
amount of toyocamycin (2 mM), that is above the Kd (40 nM)
during the co-crystallization studies. We therefore hypothesized
that the apparent mixed inhibition may result from modulation of
active sites through oligmerization.
Determination of the oligomeric states of Rio1
The steady state kinetic data suggested in addition to
competitive inhibition there is inhibition by modulation of
separate binding sites in an oligomer. This would imply that
toyocamycin binding stabilizes an oligomeric form that is less
catalytically active than the free form, the monomer. This
allosteric modulation model would also be consistent with the
observed ATP-dependent inhibition, if high concentrations of
ATP promote oligomerization and stabilize a less active oligomer
as well. In order to test this model, we determined the oligomeric
states of afRio1 under several conditions. Using analytical
ultracentrifugation, we analyzed the oligomeric states of both the
autophosphorylated and unphosphorylated forms of afRio1 in the
presence and absence of ATP/Mg
2+ and toyocamycin by
sedimentation equilibrium analysis. The average molecular
weights, determined by fitting a single species (monomer) model
to the absorbance data collected at three different speeds (18000,
22000 and 26000 rpm), are shown in Table 3. In almost every
case except for the autophosphorylated unliganded afRio1, a
single species model resulted in a poor fit as determined by
evaluation of both the residuals and (variance)
1/2. Therefore, the
data were fit to various oligomeric state models (monomer,
monomer-dimer, monomer-dimer-trimer, monomer-dimer-tetra-
mer, and monomer-tetramer equilibria). The smallest and biggest
species are observed with autophosphorylated afRio1 and, the
unphosphorylated toyocamycin bound afRio1, respectively
(Fig. 5A). The rest of the fitted data is shown in supplementary
figure S4. The results of the best fits, characterized by the simplest
model with the lowest (variance)
1/2 values, are summarized in
Table 3. Table S1 provides the (variance)
1/2 for all oligomerization
models tested and supplementary figure S5A-Q shows the
residuals. The calculated monomeric molecular weight of afRio1
is 30.1 kDa and the unliganded afRio1 fit to an average molecular
weight consistent with a dimer (60.261.1 kDa) in the unpho-
sphorylated form, and a monomer (34.161.0 kDa) in the
phosphorylated form. In the presence of ATP or ADP and
Mg
2+, the average molecular weight was between monomer and
dimer (53.661.1 kDa) for ATP and (50.861.1 kDa) for ADP for
the unphosphorylated protein. With toyocamycin present, the
average molecular weight was larger than a dimer
(71.861.2 kDa), and the best fit was obtained using a model that
assumed a mixture of monomer and tetramer. In all cases, we
cannot definitively rule out the existence of some fraction of dimer,
trimer or tetramer, since these are all theoretically possible in this
open oligomerization (i.e. an interaction interface is always
available in the oligomer). These data shows that unphosphory-
lated afRio1 forms higher order oligomers and autophosphory-
lation promotes monomerization. Addition of ATP and toyoca-
mycin to the phosphorylated form fit to a monomer-trimer model
and resulted in an increase in the average molecular weights
compared to the unligand autophosphorylated protein, the most
monomeric form. Taken together these results suggest that both
ATP and toyocamycin promote at least dimerization and perhaps
even tetramerization of afRio1 consistent with the suggested model
for inhibition by both compounds. Size exclusion chromatography
data also shows multiple oligomeric states for afRio1 depending on
ligand and phosphorylation state. Shown in Figure 5B is an
overlay of the chromatograms obtained for the phosphorylated
and unphosphorylated protein in the presence and absence of
ATP. The ligand-free phosphorylated afRio1 peak runs closest to
monomer and is shifted closer to tetramer or trimer when ATP is
present. The unphosphorylated afRio1 shows a species running
slightly larger than tetramer and a small amount of dimer. When
ATP is added, a broad peak with a mean size of dimer is observed.
These data clearly show sampling of a number of different
oligomeric states by afRio1 again consistent with the proposed
inhibition by modulation of different oligomeric states as described
above.
Since ATP also inhibits afRio1 at concentrations above 1 mM
(Fig. 2C), we were interested in whether or not a similar
mechanism of inhibition is possible for the hRio1. The oligomeric
state of hRio1 was analyzed by size exclusion chromatography
(Fig. 5C). We were unable to stabilize hRio1 protein sufficiently to
Table 2. Steady State Analysis for afRio1.
afRio1 +20 nM Toyocamycin +40 nM Toyocamycin +60 nM Toyocamycin
Km (mM) 0.4 (60.1) 0.5 (60.2) 0.2 (60.03) 0.2 (60.1)
Vmax(pmol/sec) 2.6 (60.3) 1.8 (60.3) 0.6 (60.03) 0.4 (60.1)
Ki, (nM) 10.7 26.7 3.8
Ki’(nM) 40 11.4 5.5
doi:10.1371/journal.pone.0037371.t002
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hRio1 (monomer MW =45.1 kDa) in the presence of adenosine
eluted as a tetramer (179.1 kDa), and as a mixture of monomer
and dimer when phosphorylated (Fig. 5C). Addition of ATP results
in a shift in the monomer-dimer equilibrium to mostly dimer
(104.3 kDa). This shows sampling of different oligomeric states by
hRio1 agreeing with what is observed with afRio1 suggesting that
both Rio1 kinases may employ a similar mechanism in the ATP-
dependent inhibition.
Steady state kinetics analysis of autophosphorylated
afRio1
Autophosphorylated afRio1 is monomeric in its unliganded
form as evident from sedimentation equilibrium experiments. In
an effort to determine the steady state parameters of phosphor-
ylated afRio1, the protein was subjected to the same steady state
kinetic assay and analysis as the unphosphorylated afRio1. The
phosphorylated afRio1 had a Km of 1.0 mM( 60.6) and a Vmax of
3.8 pmol/sec (Table 4, Fig. 2E). This data suggests that
phosphorylated monomeric afRio1, which has a maximum
reaction velocity (Vmax) of 3.8 pmol/sec, is more active than the
unphosphorylated afRio1, which has a Vmax of 2.6 pmol/sec. This
is consistent with the hypothesis that phophorylation promotes
monomerization resulting in a more active form of afRio1 and
association of oligomers results in a less active form as is evident
with the unphosphorylated afRio1. Inhibition studies were carried
out in the presence of 40 nM toyocamycin and the Km and Vmax
decreased with values of 0.1 mM( 60.04) and 0.5 pmol/sec
respectively. Therefore toyocamycin also inhibits the phosphory-
lated form in a similar mechanism as the unphosphorylated
afRio1, probably by promoting self-association since toyocamycin
promotes oligomerization of phosphorylated afRio1 (Table 3). In
addition, a decreased Km value indicates that toyocamycin
increases the affinity for ATP, which would be consistent with
the promotion of the ATP bound oligomeric form of afRio1.
Analysis of Interaction Interfaces in Crystal Structures
Having established that afRio1 forms higher order oligomers
depending on phosphorylation state and bound ligand, we
analyzed crystal structure lattice packing interactions for possible
interaction surfaces. Previously determined crystal structures of
unphosphorylated afRio1 bound to adenosine (ADE), ATP/Mn
2+
and ADP/Mn
2+, and the toyocamycin complex structure were
used to compare packing interfaces and identify structural
differences that may promote oligomer formation [26]. It was
previously reported that the unphosphorylated afRio1 with
adenosine bound differed from the ATP/Mn
2+ bound form in
the positioning of the flexible linker. In addition, conformational
changes were observed in the N-terminal helices of the N-lobe [9].
In this paper, we report an analysis of interaction interfaces
observed in the above structures.
The PDBe PISA server [36] was used to analyze the buried
surface area calculated between monomers in the crystal
structures. According to the PISA analysis, the protein has a low
probability of forming larger assemblies in solution based on the
identified interfaces. However, our data clearly indicate that
higher order oligomers do form in all samples except when
autophosphorylated. Therefore, we describe the interfaces ob-
served in the crystal packing as possible interaction interfaces in
solution. In the structure of the toyocamycin complex, the largest
interface (836.5 A ˚ 2 per molecule) is observed between the two
molecules of the asymmetric unit (Fig. 6A). The ATP/Mn
2+ and
ADP/Mn
2+ bound crystal structures each have four molecules per
asymmetric unit, but employ the same packing interfaces observed
in the toyocamycin complex, with two copies of a similar dimer
per asymmetric unit (Fig. 6B). The largest interface for both the
ATP (766.6 A ˚ 2) and ADP (768.4 A ˚ 2) bound structures is the one
similar to the largest interface in the toyocamycin complex. This
interface positions the helices of the C-terminal lobe of one
molecule (monomer A) in contact with both the N- and C-lobes at
the opening of the active site of the second molecule (monomer B),
almost completely occluding that active site (Fig. 3, 6A and B). The
N-lobe helix 2 of monomer B and the C-lobe helix, aFo f
monomer A interact via hydrogen bonds between B:Glu 23 and
B:Glu 22 and A:Arg 237, B:Glu 22 and A:Lys 241, A:Lys 25 and
A:Tyr 242. In addition, B:Glu 29 interacts with A:Lys 168
(Fig. 6A). The C-terminal lobe of monomer B interacts with the C-
terminal lobe of monomer A via conserved B:Tyr 200, which is in
hydrophobic contact with A:Leu 252, A:Lys 253, A:Glu 249 and
A:Phe 248 from the terminal a helix of monomer A. In addition,
there is a hydrogen bond between B:Glu 162 and A:Arg 233. Glu
162 also participates in a water-mediated hydrogen bond with the
39 OH of the toyocamycin ribose moiety. This interface is not
observed in the crystal structure of afRio1 bound to ADE (Fig. 6C).
The largest interface observed in the ADE bound structure
(1023.3 A ˚ 2) instead positions the N-lobe of one monomer
(monomer A) between the N- and C-lobes of a symmetry related
Table 3. Analysis of Sedimentation Equilibrium Data for Various afRio1 Complexes.
Sample
Weight Averaged MW
(kDa) Best Fit Model (Variance) K Estimate Kd (M)
afRio1 60.261.1 Monomer- tetramer 8.0610
23 6.1610
26
afRio1+ toyocamycin 71.861.2 Monomer- tetramer 1.8610
22 1.5610
26
afRio1+ATP 53.661.1 Monomer-dimer 2.8610
22 3.1610
26
afRio1+ADP 50.861.1 Monomer-dimer 2.4610
22 6.3610
26
Phosphorylated afRio1 34.161.0 Monomer 3.1610
22 N/A
Phosphorylated afRio1+ATP 47.661.1 Monomer-trimer 8.8610
23 7.0610
26
Phosphorylated afRio1+ toyocamycin 46.261.2 Monomer-trimer 1.3610
22 6.4610
26
afRio1 Y200D 70.661.1 Monomer- tetramer 9.2610
23 1.0610
27
afRio1 Y200D +toyocamycin 48.261.1 Monomer-trimer 9.3610
23 1.2610
25
afRio1Y200D +ATP 46.861.1 Monomer-trimer 9.4610
23 7.3610
26
doi:10.1371/journal.pone.0037371.t003
Interaction of Rio1 Kinase with Toyocamycin
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37371monomer (monomer B), on one side of the active site, close to the
hinge (Fig. 6C). The interface is extensive and positions the first
three N-terminal helices of monomer A in contact with monomer
B. This interface does not result in occlusion of the active site, and
in fact, a second symmetry related molecule positions its flexible
linker of one monomer (monomer A), which contains the
autophosphorylation site (Ser 108), at the entrance to the active
site of monomer B. In summary, different, mutually exclusive,
interaction interfaces are observed in the crystal structures of
afRio1/ADE complex and the afRio1/toyocamycin complex, but
the same packing is observed for afRio1 when toyocamycin, ATP/
Mn
2+, or ADP/Mn
2+ is bound (Fig. 7A). This suggests that Rio1
may exist in at least two distinct dimeric/oligomeric states, and
that the toyocamycin bound afRio1 favors the conformation
observed in the ATP bound afRio1. To further support the
conformational similarity between ATP and toyocamycin com-
plexes, a root mean square deviation (RMSD) plot of afRio1
bound to ATP and ADE calculated using the afRio1/toyocamycin
complex as the reference demonstrates that afRio1/ATP shows
less deviation from afRio1/toyocamycin compared to the afRio1/
ADE (Fig S6A). In addition, an RMSD plot of residues within 8 A ˚
from the ligand’s center shows less deviation between the afRio1/
ATP and toyocamycin structures (Fig S6B).
The involvement of Tyr 200 in the interaction interfaces is
notable, since Tyr 200 is either Phe or Tyr in all RIO kinases, and
is part of the catalytic loop containing the catalytic Asp and Asn
residues. In the interfaces identified in the crystal structures of the
afRio1 complexes with ATP and toyocamycin, Tyr200 interacts
with several residues via hydrophobic contact (Fig. 6A). Since the
interfaces observed in the crystal lattice may not be the actual
interface in solution, we tested whether Tyr 200 plays a role in
dimerization of afRio1 when toyocamycin or ATP is bound. Tyr
200 was mutated to Asp (Y200D) in order to break the predicted
hydrophobic interactions in the interface, and determined its
oligomeric state by analytical ultracentrifugation in the presence
and absence of bound ligand. Sedimentation equilibrium data for
the unliganded Y200D mutant fit to an average molecular weight
of 70.861.1 kDa assuming a single-species model and fit best to a
monomer-tetramer model (Table 3, Fig. S4 G-H), indicating that
oligomerization is not significantly affected by the mutation in the
unliganded form. However, when toyocamycin or ATP/Mg
2+ is
added, the average molecular weight drops to 48.261.1 kDa and
46.861.1 kDa respectively, with best fit to a monomer-trimer
model in both cases indicating that mutation of Tyr 200
Figure 5. Characterization of the oligomeric states of Rio1. A.
Sedimentation equilibrium data collected at 18,000 rpm with residuals
and best fit curves for phosphorylated afRio1 (blue dots; single species
model) and the afRio1/toyocamycin complex (red dots; monomer-
tetramer model) B. Size exclusion chromatography plots for afRio1 in an
unphosphorylated state (red), unphosphorylated afRio1 with ATP
(purple), phosphorylated afRio1 (blue) and phosphorylated afRio1 with
ATP bound (green). C. Size exclusion chromatography plots for hRio1
unphosphorylated state with adenosine bound (red), unphosphorylated
hRio1 with ATP bound (green), phosphorylated hRio1 (purple). Plot for
standards used in column calibration is overlaid in black with numbers
indicating the known molecular weight (kDa) for the standards in each
peak.
doi:10.1371/journal.pone.0037371.g005
Table 4. Steady State Analysis of Phosphorylated afRio1.
Phosphorylated afRio1 +40 nM Toyocamycin
Km (mM) 1.0 (60.6) 0.1 (60.03)
Vmax (pmol/sec) 3.8 (60.1) 0.5 (60.04)
doi:10.1371/journal.pone.0037371.t004
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molecular weights of toyocamycin and ATP/Mg
2+ Y200D
complexes are lower compared to the wild-type complexes in
both cases (Table 3). This data demonstrates that the mutation of
Tyr 200 compromises oligomerization in the presence of
toyocamycin or ATP/Mn
2+, but has no effect on that of the
ADE complex. This supports the idea that these complexes utilize
different interfaces for oligomerization, and is consistent with the
use of the observed crystallographic interfaces.
How afRio1 Tetramers Form
In all afRio1 structures, the dimer formed by the interfaces
described above would result in open oligomers, in that the
interactions are heterologous, formed by two separate surfaces on
the molecules. Although this type of interaction is uncommon, it
has been observed for other protein kinases, for example
Epidermal Growth Factor Receptor (EGFR), which forms an
asymmetric dimer prior to activation [37]. This asymmetry means
that a second interface is available for higher order oligomer
formation for both monomers. Therefore, tetramers observed in
AUC experiments could be formed from interaction between
dimers. Tetramers predicted based on analysis of crystal contacts
for toyocamycin, ATP and adenosine bound forms are shown in
supplementary figure S7. Analysis of the adenosine complex
revealed that interaction between dimers utilizing the largest
interaction interface would bury an additional 1055 A ˚ 2 of surface
area, and present the autophosphorylation site to the active site.
For the toyocamycin and ATP complexes, an additional 881 and
819 A ˚ 2 is buried respectively. Therefore, it is possible that dimer
formation nucleates higher order oligomers, and anything that
stabilizes the dimer would promote formation of the tetramer. In
this model, trimers could be formed by addition of a monomer to a
dimer, and would be observed when the proportion of monomer is
increased, as seen for autophosphorylated protein in the presence
of ATP/Mg
2+ and toyocamycin.
AfRio1 Changes Oligomeric Forms via a Conformational
Switch
Since toyocamycin is an adenosine analog, and more closely
resembles adenosine than ATP, it is surprising that it selects the
ATP-bound conformation, and binds more tightly than ATP/
Mg
2+. Therefore, we hypothesized that there must be structural
conformational changes conserved between the ATP and
toyocamycin bound structures that are absent in the ADE bound
structure and influence the choice of interaction interface. Upon
closer inspection of the active sites of the structures with adenosine,
toyocamycin and ATP bound, we observed a difference in
positioning of the loop containing the metal binding residue,
Asp 212 (metal-binding loop; Fig. 7B). Specifically, in the
adenosine bound structure, the backbone carbonyl oxygen bond
of Ile 211 is pointing into the ATP binding pocket, while in the
ATP and toyocamycin bound structures, there is a peptide flip that
positions the Ile 211 carbonyl oxygen bond in the opposite
direction, resulting in a 3.8 A ˚ shift in position of the carbonyl
oxygen. A simulated annealing Fo-Fc omit map for the afRio1-
toyocamycin complex, calculated after omitting residues 211–212
revealed density for the peptide bond supporting the peptide flip
that is observed between the adenosine and toyocamycin
complexes (Fig. S8). The change produces a shift in the metal-
binding loop containing residues Ile 211 to Gln 215, such that the
Figure 6. Dimer interfaces of afRio1 complexes. A. Interactions at
the afRio1/toyocamycin (Toyo) dimer interface. Separate monomers are
colored in cyan and green. Residues shown in stick participate in direct
interactions between the monomers. Polar interactions are shown as
dashed lines. B. Dimer observed for the afRio1/ATP/Mn
2+ complex as
determined by analysis of crystal structure PDB code 1ZP9, with
monomer in magenta oriented similar to monomer A in Fig. 3. C. Dimer
observed for the afRio1/adenosine (Ade) complex as determined by
analysis of crystal structure PDB code 1ZTF, with monomer in yellow
oriented similar to monomer A of the afRio1/toyocamycin complex
depicted in Fig. 2.
doi:10.1371/journal.pone.0037371.g006
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shifted by 2.1 A ˚. The result is a hydrogen bond between the Gln
215 side chain and the Asp 212 carbonyl oxygen in the
toyocamycin and ATP structures, and a shift of the flexible loop
of afRio1 away from the active site (Fig. 7B). An inspection of the
overall alignment of the monomers for the various complexes also
reveals a shift in the positioning of the N-lobe relative to the C-
lobe in the adenosine complex, resulting in a more closed cleft
between them when ATP or toyocamycin is bound (Fig. 7A).
Discussion
Our results show a tight binding compound, toyocamcin that
has high affinity for both A.fulgidus and human Rio1 and confers
similar conformational changes as those observed in the afRio1/
Mn
2+ complex. Whereas toyocamycin inhibits the maturation of
40 S subunit during ribosome biogenesis [19–22], Rio1 is required
for the maturation of this small subunit. We therefore present the
first identified target of toyocamycin during this process.
In characterizing this system we observe an apparent mixed
inhibition that may result from by the formation of oligomers that
are less catalytically active. This is supported by both structural
analysis and solution-based studies (sedimentation equilibrium and
size exclusion) that show the presence and sampling of multiple
oligomeric states depending on the ligand bound (toyocamycin or
ATP) as well as the phosphorylation state of Rio1. Structural
analysis of interacting interfaces in crystal structures of toyocamy-
cin and ATP bound complexes reveal occlusion of the active site in
participating monomers and hence the approach of substrate. In
effect, both toyocamycin and ATP stabilize an oligomeric form of
the protein in which the active site of only one monomer in any
oligomer is accessible to the substrate supporting inhibition by
oligomerization. Substrate inhibition by high concentrations of
ATP could be a biological regulatory mechanism similar to that
observed in various enzymes, including kinases such as phospho-
fructokinase, that employ substrate inhibition as a regulatory
feedback mechanism [38–41].
Though we can explain inhibition by association of oligomers, it
is not clear that we can definitively define the inhibition model due
to the complexities of our system. Detailed steady state inhibition
experiments with a specific-Rio1 substrate would aid in better
explaining the inhibition mechanism. What is conclusive from our
data is that afRio1 oligomerization is promoted by ligand-binding,
and thus oligomerization may play a role in substrate inhibition
and regulation of enzyme activity. This has previously been
observed in other enzymatic systems, such as HIV integrase, which
is inhibited by a shift in its oligomeric equilibrium from an active
form to an inactive tetramer that is promoted by ligand binding
[42].
The crystal packing interfaces of all the complexes were
analyzed and show similar packing for the toyocamycin and
ATP complex, but a distinct set of packing interfaces for the ADE
complex, despite toyocamycin’s resemblance to adenosine,
suggesting possible quaternary structure for the oligomers. A
conformational switch mediated by a single peptide backbone flip
at Ile 211 was identified when both the toyocamycin and ATP/
Mg
2+ bound forms were compared to the adenosine complex. This
conformational change causes a significant shift of the metal-
binding loop. As a result, the perturbation of structure caused by
the peptide flip is disseminated to the positioning of the N-lobe and
C-lobe relative to each other, and thereby the choice of crystal
packing interaction interface is affected. If the crystal packing
interface reflects the interfaces used in solution, the peptide flip can
be regarded as a switch between two choices of higher order
oligomeric states. Regulation of the protein might be enacted by
changes in the number of protein molecules in which the switch is
flipped on or off through the type and concentration of the ligand.
This discovery may indicate that the enzymatic activity of Rio1 is
regulated by its oligomeric state. Since the interfaces have not been
extensively biochemically validated, we cannot be certain that they
Figure 7. Structural comparison of afRio1 dimers. A. Overlay of the dimers for the adenosine (yellow), toyocamycin (cyan) and ATP/Mn
2+
(magenta) complexes. The C-lobe (residues 217 to 257) of monomer A were aligned for the superposition. Figure shows the differences in positioning
of monomer B, as well as occlusion of the active site by monomer B in the ATP and toyocamycin complexes. In addition, the N-terminal helices of
monomer A in the adenosine complexes are shifted (double arrow, 8 to 9 A ˚) relative to the other complexes. B. Conformational switch observed by
the active site of all three complexes (colored as in A with monomer A aligned). A peptide flip is observed that repositions the carbonyl oxygen of Ile
211 (indicated by *; ,140u rotation, 3.8 A ˚ shift) as a result of steric clash with the cyano moiety of toyocamycin, and interactions of Asp 212 with
metal ion in the ATP complex. The metal binding loops in the ATP and toyocamycin complexes are consequently shifted (double arrows, 1.6 to 2.0 A ˚).
This results in reorganization of active site residues such as Gln 215 and His 194.
doi:10.1371/journal.pone.0037371.g007
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interfaces is supported by the mutation of Tyr 200 that affects
oligomerization for toyocamycin and ATP complexes, but not the
ADE complex.
The data presented in this analysis suggest that Rio1 kinase
shows some of the characteristics of a morpheein [43,44]. The
morpheein model of allostery was first described for human
porphobilinogen synthase, and is characterized by more than one
distinct monomer conformations in the dissociated state, and
multiple distinct quaternary assemblies from these as a result
[45,46].
In an effort to assign a role of Rio1 autophosphorylation, we
analyzed the effect of phosphorylating Rio1 and discovered that
autophosphorylation promotes monomerization. Steady state
kinetics experiments indicate that this form is more active than
the unphosphorylated afRio1 based on the maximum catalytic
velocity (Vmax). Therefore afRio1 activity may be regulated by its
oligomerization properties and autophosphorylation promotes the
more active free form, the monomer. Human Rio1 could function
in a similar manner as it is evident that autophosphorylated hRio1
promotes monomerization to some extent. In fact, Angermayr and
colleagues have shown that yeast Rio1 kinase can by phosphor-
ylated by Casein Kinase II and this phosphorylation results in
activation and degradation of the protein in a cell cycle phase
dependent manner [47]. Recent reports also indicate that hRio1
kinase activity is necessary for association with precursors of 40 S
and is required for recycling the endonuclease hNob1 and the
dimethyltransfase hDim2 [48]. This could mean that the hRio1
oligomeric state could be regulated both by autophosphorylation
and phosphorylation by other kinases. In addition, Rio1 has been
shown to participate in the formation of protein complexes in the
cell [49], and regulation of its oligomeric state may also influence
interaction with other proteins. Taken together, these data would
assign a role for autophosphorylation in modulating the activity of
Rio1 kinase, both in enzymatic activity and in protein-protein
interactions.
Finally we present the first crystal structure of toyocamycin
bound to its first identified ribosome processing target, Rio1. The
tight binding of toyocamycin to the afRio1 ATP binding pocket
provides a tool that can be used in future experiments to identify
Rio1 substrates by various methods that utilize radiolabeled ATP
analogs to capture kinase substrates [50–53]. A more recent
unbiased validation assay that couples both functional proteomics
and chemical genetics for identifying kinase substrate using
inhibitors can also be employed using our system [54].
Supporting Information
Figure S1 Thermal shift curves for four compounds (Toyoca-
mycin, ATP, Sangivamycin and 7-methylinosine ) that were
screened for binding to afRio1. Each curve represents one of the
three replicate reactions. Toyocamycin (red) shows the largest shift
in melting temperature.
(TIF)
Figure S2 Alignment of afRio1-toyocamycin complex’s active
site indicating an almost perfect superposition of the active site of
the two molecules found in the asymmetric unit.
(TIF)
Figure S3 Overlay of afRio1/toyocamycin (green) and afRio1/
ATP (purple) binding sites shows that both ligands bind to the
same site. Residues in the binding site are labeled.
(TIF)
Figure S4 Sedimentation equilibrium data collected at three
different speeds; 18,000 rpm (blue dots), 22,000 rpm (green dots),
and 26,000 rpm (red dots). The fitted data was analyzed at all
three speeds and at the same concentration (0.25 mg/ml). The
residuals for each fit are provided in the top panel and show
random distribution in most. A. AfRio1 with adenosine bound.
B. AfRio1 with ATP bound. C. AfRio1 with toyocamycin bound.
D. AfRio1 with ADP bound. E. Phosphorylated afRio1 with
Toyocamycin bound. F. Phosphorylated afRio1 with ATP bound.
G. The afRio1 Y200D mutant with no ligand bound. H. The
afRio1 Y200D mutant with toyocamycin bound.
(TIF)
Figure S5 Residuals for sedimentation equilibrium data col-
lected at three different speeds; 18,000 rpm (blue dots),
22,000 rpm (green dots), and 26,000 rpm (red dots). The fitted
data was analyzed at all three speeds and at the same
concentration (0.25 mg). A-C. AfRio1 with Toyocamycin bound
fitted to: A. monomer-dimer, B. dimer, C. monomer-trimer. D.
AfRio1 fitted to monomer-dimer. E. AfRio1 fitted to dimer. F.
AfRio1 with ATP bound fitted to monomer. G. AfRio1 with ADP
bound fitted to monomer. H. Phosphorylated afRio1 with ATP
bound fitted to monomer. I. Phosphorylated afRio1 with ATP
bound fitted to monomer-dimer. J. Phosphorylated afRio1 with
toyocamycin bound fitted to monomer. K. Phosphorylated afRio1
with toyocamycin bound fitted to monomer-dimer. L. AfRio1
Y200D mutant fitted to monomer-dimer. M. AfRio1 Y200D fitted
to monomer-trimer. N. AfRio1 Y200D mutant with ATP bound
fitted to a monomer. O. AfRio1 Y200D mutant with ATP bound
fitted to monomer-dimer. P. AfRio1 Y200D mutant with
toyocamycin bound fitted to a monomer. Q. AfRio1 Y200D
mutant fitted to monomer-dimer.
(TIF)
Figure S6 Plots of the root mean square deviations (RMSD) for
afRio1 complexes. All calculations were carried out using the
toyocamycin-bound structure as the reference. A. RMSD
comparisons over all residues of afRio1 bound to ATP and
adenosine (ADE). Larger deviations are observed with the
adenosine structure. B. RMSD comparison of residues within
8A ˚ radius from the ligand’s center. The plots demonstrate that
the afRio1-ATP structure show smaller deviations from the
toyocamycin bound structure.
(TIF)
Figure S7 Tetramers predicted from crystal packing interactions
for the afRio1/toyocamycin, afRio1/ATP and afRio1/ADE
tetramers. A. AfRio1/ATP tetramer with ATP bound to each
monomer. B. AfRio1/toyocamycin tetramer with toyocamycin
bound to each monomer (similar to the afRio1/ATP tetramer). C.
AfRio1/adenosine tetramer with adenosine bound to each
monomer (different from A. and B.). Tetramers were generated
by displaying symmetry related molecules with the largest and
second largest buried surface area between them.
(TIF)
Figure S8 A simulated annealing Fo-Fc omit map calculated
after omitting residues 211–212 (contoured at 2.5s) reveals
electron density for the Ile 211-Asp 212 peptide bond in the
afRio1-toyocamycin complex (cyan). The toyocamycin (cyan) and
ATP (magenta) show the backbone carbonyl oxygen bond of Ile
211 pointing away from the ATP-binding pocket. The associated
peptide bond is flipped in the afRio1-adenosine complex (yellow),
which results in the carbonyl oxygen bond pointing into the
binding pocket.
(TIF)
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